{"id":"https://openalex.org/W4404064304","doi":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","title":"504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation","display_name":"504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation","publication_year":2024,"publication_date":"2024-11-01","ids":{"openalex":"https://openalex.org/W4404064304","doi":"https://doi.org/10.1136/jitc-2024-sitc2024.0504"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2024-sitc2024.0504","doi":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004615488","display_name":"Chuan Wang","orcid":"https://orcid.org/0000-0002-0501-3092","observed_orcids":["https://orcid.org/0000-0002-0501-3092"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Chuan Wang","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100404918","display_name":"Ning Zhang","orcid":"https://orcid.org/0000-0003-3136-8417","observed_orcids":["https://orcid.org/0000-0003-3136-8417"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ning Zhang","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102753709","display_name":"Xinling Zhang","orcid":"https://orcid.org/0000-0003-3783-0465","observed_orcids":["https://orcid.org/0000-0003-3783-0465"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xinling Zhang","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yongwang Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yongwang Li","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101677401","display_name":"Xuelian Liu","orcid":"https://orcid.org/0000-0003-1676-4593","observed_orcids":["https://orcid.org/0000-0003-1676-4593","https://orcid.org/0009-0002-7345-7004"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xuelian Liu","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101982080","display_name":"Yongli Yang","orcid":"https://orcid.org/0000-0002-6271-0281","observed_orcids":["https://orcid.org/0000-0002-6271-0281"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yongli Yang","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019068861","display_name":"Jingyu Sun","orcid":"https://orcid.org/0000-0002-9812-3046","observed_orcids":["https://orcid.org/0000-0002-9812-3046"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jingyu Sun","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115587912","display_name":"Fei Ma","orcid":"https://orcid.org/0009-0002-5388-9125","observed_orcids":["https://orcid.org/0009-0002-5388-9125"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Fei Ma","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006294467","display_name":"Mengyao Zhu","orcid":"https://orcid.org/0000-0002-9515-8112","observed_orcids":["https://orcid.org/0000-0002-9515-8112","https://orcid.org/0000-0002-7898-173X"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Mengyao Zhu","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101112675","display_name":"Jianxin Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jianxin Yang","raw_affiliation_strings":["CStone Pharmaceuticals, Shanghai, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CStone Pharmaceuticals, Shanghai, Shanghai, China","institution_ids":["https://openalex.org/I4405267831"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267831"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A568","last_page":"A568"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":1.0},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.8809999823570251},{"id":"https://openalex.org/keywords/trispecific-antibodies","display_name":"trispecific antibodies","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8640000224113464},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.6259999871253967},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.7059999704360962},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.7360000014305115},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7429999709129333},{"id":"https://openalex.org/keywords/humanized-mouse-model","display_name":"humanized mice","score":0.46799999475479126},{"id":"https://openalex.org/keywords/cynomolgus-monkey-pharmacokinetics","display_name":"cynomolgus monkey pharmacokinetics","score":0.7519999742507935},{"id":"https://openalex.org/keywords/antibody-stability","display_name":"antibody stability","score":0.3310000002384186},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.4519999921321869},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6060000061988831},{"id":"https://openalex.org/keywords/vascular-normalization","display_name":"vascular normalization","score":0.5649999976158142},{"id":"https://openalex.org/keywords/t-cell-proliferation","display_name":"T cell proliferation","score":0.48899999260902405},{"id":"https://openalex.org/keywords/ki-67","display_name":"Ki-67","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.49772194027900696},{"id":"https://openalex.org/C2777212361","wikidata":"https://www.wikidata.org/wiki/Q5127848","display_name":"Class (philosophy)","level":2,"score":0.45916518568992615},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.4105718731880188},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4024132192134857},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35824936628341675},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2530289888381958},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.05904793739318848}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2024-sitc2024.0504","doi":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2024-sitc2024.0504","doi":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2024-sitc2024.0504","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409630635","https://openalex.org/W7154731064","https://openalex.org/W4415941818","https://openalex.org/W4388079291","https://openalex.org/W4393087551","https://openalex.org/W4415900434","https://openalex.org/W4409628099","https://openalex.org/W7162575901","https://openalex.org/W3011071920","https://openalex.org/W4388067990"],"abstract_inverted_index":{"Background":[0],"Immune":[1],"checkpoint":[2],"blockage":[3,28],"(ICB)":[4],"has":[5,29,251],"become":[6],"a":[7,126,158,162,167,259,276,286,292,311,324],"standard-of-care":[8],"treatment":[9,317],"for":[10,315],"various":[11,319],"tumor":[12,82,108,115],"types.":[13],"While":[14],"the":[15,67,93,138,203,228,302,316],"clinical":[16,331],"benefits":[17],"of":[18,95,141,198,213,304,318],"PD-1":[19],"inhibition":[20],"are":[21],"well":[22,282],"established,":[23],"combining":[24],"it":[25],"with":[26,157,207,219,258],"CTLA-4":[27],"demonstrated":[30,253,297],"enhanced":[31],"efficacy.":[32],"However,":[33],"anti-CTLA-4":[34,63],"agents":[35],"also":[36,252,296],"induces":[37],"significant":[38],"immune-related":[39],"adverse":[40],"events":[41],"(irAEs),":[42],"thus":[43],"restricting":[44],"its":[45,241],"anti-tumor":[46,139,238],"effect.":[47],"One":[48],"strategy":[49],"to":[50,55,60,65,78,106,135,176,240,263],"overcome":[51],"this":[52],"problem":[53],"is":[54,215,310],"build":[56],"bispecific":[57],"molecules":[58],"aiming":[59],"1)":[61],"attenuate":[62],"arm":[64,134,165,212],"balance":[66],"immune-toxicity":[68],"and":[69,73,89,118,155,166,184,223,248,256,280,291],"immune-efficacy":[70],"(e.g.":[71,87],"cadonilimab":[72],"KN046);":[74],"2)":[75],"preferentially":[76,191],"bind":[77,175],"PD-1/CTLA-4":[79],"double":[80,194],"positive":[81,195],"infiltrating":[83],"T":[84,120,287,305],"cells":[85,196,306],"(TILs)":[86],"volrustomig":[88],"vudalimab).":[90],"To":[91],"improve":[92,119],"effect":[94],"ICB,":[96],"VEGF":[97],"inhibitors":[98],"including":[99],"bevacizumab,":[100],"ramucirumab,":[101],"lenvatinib,":[102],"etc.":[103],"were":[104],"applied":[105],"interrupt":[107],"angiogenesis,":[109],"hence":[110],"promote":[111],"vascular":[112],"normalization":[113],"in":[114,269],"immune":[116,231],"microenvironment,":[117],"lymphocyte":[121],"infiltration.":[122],"We":[123],"therefore":[124],"developed":[125],"trispecific":[127,313],"molecule,":[128,146],"CS2009,":[129],"which":[130,179],"adds":[131],"an":[132],"anti-VEGF":[133,160,211],"further":[136,330],"increase":[137],"activity":[140],"ICB.":[142,326],"Methods":[143],"The":[144,210],"lead":[145],"J30":[147,172,190,214,235,250,274,299,309],"was":[148,180,281],"screened":[149],"out":[150],"from":[151],"100+":[152],"multispecific":[153],"molecules,":[154],"constructed":[156],"bivalent":[159],"arm,":[161],"monovalent":[163,168],"anti-PD-1":[164],"anti-CTLA4":[169],"arm.":[170],"Results":[171],"can":[173],"concurrently":[174],"three":[177],"targets,":[178],"validated":[181],"by":[182,202],"protein-based":[183],"cell-based":[185],"binding":[186,200],"assays.":[187],"In":[188,227],"addition,":[189],"targets":[192],"PD-1/CTLA4":[193],"because":[197],"avidity-driven":[199],"triggered":[201],"two":[204],"functional":[205,217],"arms":[206],"balanced":[208],"affinity.":[209],"fully":[216],"assessed":[218],"both":[220],"reporter":[221],"assay":[222],"HUVEC":[224],"proliferation":[225,289],"assay.":[226],"studies":[229,268],"using":[230],"competent":[232],"humanized":[233],"mice,":[234],"showed":[236],"superior":[237],"activities":[239],"major":[242],"competitors":[243],"such":[244],"as":[245,285,323],"cadonilimab,":[246],"AK112":[247],"volrustomig.":[249],"favourable":[254],"stability":[255],"developability,":[257],"yield":[260],"level":[261],"similar":[262],"monoclonal":[264],"antibodies":[265],"(mAbs).":[266],"PK/toxicity":[267],"cynomolgus":[270],"monkeys":[271],"indicated":[272],"that":[273,298],"had":[275],"mAb-like":[277],"PK":[278],"profile":[279],"tolerated.":[283],"Ki67":[284],"cell":[288],"marker":[290,295],"reliable":[293],"PD":[294],"could":[300],"induce":[301],"activation":[303],"remarkably.":[307],"Conclusions":[308],"promising":[312],"molecule":[314],"advanced":[320],"solid":[321],"tumors":[322],"next-generation":[325],"Current":[327],"data":[328],"supports":[329],"research":[332],"on":[333],"CS2009.":[334]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2024-11-06T00:00:00"}